Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1268-1280
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1268
Prognostic analysis of related factors of adverse reactions to immunotherapy in advanced gastric cancer and establishment of a nomogram model
Xu-Xu He, Bang Du, Tao Wu, Hao Shen
Xu-Xu He, Department of Surgery, Fudan University Affiliated Zhongshan Hospital (Qingpu Branch), Shanghai 201700, China
Bang Du, Hao Shen, Department of Surgery, Anhui Provincial Red Cross Society Hospital, Hefei 230031, Anhui Province, China
Tao Wu, Department of General Surgery, West China Hospital of Sichuan University, Chengdu 610044, Sichuan Province, China
Co-first authors: Xu-Xu He and Bang Du.
Author contributions: He XX and Du B wrote the manuscript, and are the co-first authors of this manuscript; Wu T and Shen H collected the data and guided the study; and all authors reviewed, edited, and approved the final manuscript and revised it critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.
Institutional review board statement: Our study has been approved by Medical Research Ethics Approval Committee (2023010122HN11C).
Informed consent statement: Informed written consent was obtained from the patients for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at email address: xuxu19930318@126.com.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xu-Xu He, MD, Doctor, Department of Surgery, Fudan University Affiliated Zhongshan Hospital (Qingpu Branch), No. 1158 Xiayang Street Park East Road, Qingpu District, Shanghai 201700, China. xuxu19930318@126.com
Received: December 14, 2023
Peer-review started: December 14, 2023
First decision: January 6, 2024
Revised: January 10, 2024
Accepted: March 4, 2024
Article in press: March 4, 2024
Published online: April 15, 2024
Processing time: 118 Days and 17 Hours
Core Tip

Core Tip: To explore the characteristics and predictors of immune-related adverse reactions (irAEs) in advanced gastric cancer patients receiving immunotherapy with programmed death protein-1 (PD-1) inhibitors, and to analyze the correlation between irAEs and patient prognosis. A total of 132 patients were followed up, of whom 63 (47.7%) developed irAEs. The clinical characteristics of the two groups were compared, and there were statistically significant differences in age ≥ 65 years, Ki-67 index, white blood cell count, neutrophil count, and regulatory T cell (Treg) count between the two groups (all P < 0.05). Multivariate logistic regression analysis showed that Treg count was a protective factor affecting irAEs occurrence (P = 0.030).